The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and <i>BRAF<sup>V600E</sup></i> Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤ 18 Years Old.

Creative Commons License

Giles Senyurek Y., Iscan Y., Sormaz I. C., Poyrazoglu Ş., Tunca F.

Journal of clinical research in pediatric endocrinology, vol.14, pp.196-206, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2022
  • Doi Number: 10.4274/jcrpe.galenos.2022.2021-10-4
  • Journal Name: Journal of clinical research in pediatric endocrinology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.196-206
  • Keywords: BRAF(V600E) mutation, dynamic risk stratification, pediatric thyroid cancer, thyroid cancer, MANAGEMENT GUIDELINES, BRAF MUTATION, CHILDREN, RECURRENCE, ADOLESCENTS, CHILDHOOD, CARCINOMA, FEATURES, REMISSION, PROGNOSIS
  • Istanbul University Affiliated: Yes


Objective: This study aimed to evaluate the role of risk stratification by the American Thyroid Association (ATA) pediatric thyroid cancer risk levels and BRAF(V600E) mutation to predict the response to treatment in papillary thyroid cancer (PTC) patients <= 18 years old.